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or the past several years, preimplant surgery has made it possible, through the use of bone grafting, to obtain a more or less total reconstitution of the alveolar walls. This first therapeutic step allows the adequate positioning of the implants and the long-term success of implant-supported reconstruction. [1] [2] [3] [4] [5] However, these large-scale grafts often require autogenous bone taken from the patient's calvaria (parietal bone is very often used in France) [6] [7] [8] or iliac crest. 9 -11 It implies a rather significant operation under general anesthesia, with all of the risks associated with hospitalization and with donor site morbidity. The relative seriousness of such a procedure discourages many patients and dissuades them from using these treatments which, however, are essential to their facial rehabilitation, after many years of psychological, esthetic, and functional discomfort.
To simplify the graft protocols, bone substitutes have been considered as an alternative solution to the autogenous grafts. These substitution biomaterials can be divided into 3 overall groups: entirely synthetic products (Cerasorb, Nanobone, etc.), xenografts (lyophilized bovine bone, BioOss type, etc.), and allogeneic grafts (human bone from a tissue bank). This allogeneic bone is generally considered as an efficient and secure product. [12] [13] [14] Nonetheless, its use during large-scale bone grafting is relatively undeveloped, owing to the long waiting period necessary for its proper integration before implants can be loaded, and to their mechanical properties, which make surgical manipulation difficult. 15 Therefore, although they are frequently used for sinus grafts, 16 ,17 their use during significant bone grafting for alveolar ridges thickening remains limited.
In France, the use of Choukroun's platelet-rich fibrin (PRF) has played a significant role in the evolution of 27 The protocol is very simple: whole blood is drawn in 10-mL tubes without anticoagulant 27 and is immediately centrifuged at around 400 g for 12 minutes (Process protocol, Nice, France). Within few minutes, the absence of anticoagulant allows the activation of the majority of the platelets contained in the sample, in contact with the tube walls, thus triggering a coagulation cascade. The fibrinogen is at first concentrated in the upper part of the tube, until the effect of the circulating thrombin transforms it into a fibrin network. The result is a fibrin clot located in the middle of the tube and soaked with acellular plasma, with a maximum number of platelets caught in the fibrin mesh.
When used as a membrane, PRF enables the protection of operative sites from outside aggression and serves as a matrix to accelerate the healing of wound edges, 28 much like a fibrin bandage. 22, 29 When mixed with the graft material, the fibrin clot functions as a biological connector between the different elements of the graft, and as a matrix which favors neo-angiogenesis, the capture of stem cells, and the migration of osteoprogenitor cells to the center of the graft. 22, 23 The addition of PRF to graft material could therefore become a serious opportunity to develop new therapeutic procedures by improving the integration of bone substitution materials during preimplant grafting.
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The clinical case that follows is a detailed illustration of this concept.
CLINICAL ILLUSTRATION

The Initial Situation
A 52-year-old female patient consulted on December 4, 2002. Because of a series of infections and a severe periodontal disease which was not immediately diagnosed, she had for many years been wearing a partial removable dental prosthesis. The 3 remaining teeth (17, 26, 27), secondarily infected, had induced a polypoid reaction in the mucous membrane of the right sinus. Given her young age, this prosthesis was, for her, a source of permanent psychological suffering and a symbol of the mutilation of her face. Under the prosthesis, the maxillary alveolar ridges had already undergone significant centripetal resorption, both in height and-especially-in thickness. It was thus impossible to place axial implants without a preimplant reconstruction of the maxillary using bone grafts. This diagnosis was confirmed by the computed tomography scan examination, which clearly showed a subantral bone height of 3 mm and anterior ridges measuring less than 3 mm thick ( Fig. 1) . It was decided to first eliminate all remaining maxillary and mandibular sources of infection. Then, a complete removable maxillary prosthesis and a partial mandibular prosthesis were temporarily used.
After being clearly and openly informed on the different therapeutic options available to her, the patient accepted a multiphase treatment plan combining preimplant allografts and complete implant-supported maxillary rehabilitation.
Graft Surgery
During the preimplant phase, it was necessary to reconstruct resorbed maxillary bone structures. Indeed, the remaining architecture was unsuitable for adequate implantation. The entire surgical site was first opened, then the medullar bone along the vestibular side of the anterior alveolar ridges was stimulated, to facilitate proper vascularization and integration of the graft.
In the posterior area, the 2 sinuses were opened to be filled (Fig. 2) .
The bone graft consisted of a combination of freeze-dried bone allograft Phoenix (TBF, Mions, France) and of PRF. This mixture, soaked in metronidazole (0.5% solution), was used to fill the sinuses and to considerably thicken the vestibular side of the anterior and central alveolar ridges (Fig. 3, A) . To protect the graft and to accelerate healing of the crestal incision, a large quantity of PRF membranes was used to cover the entire grafted area (Fig. 3, B) . Sutures should keep the PRF membranes flattened under the flap (Fig. 3, C) . Three days after the surgery, the sutures were removed. The PRF membranes acted as fibrin bandages, enabling quick closure of the surgical site despite the substantial volume of bone added (Fig. 4) . Three months after graft surgery and healing on a PRF fibrin bed, gingival tissue looked thick and keratinized. Note that the PRF membranes were obtained using the standard protocol described in the scientific literature. 18, 19 To avoid pressure on the grafted material (it could induce mobility and fibrosis of the graft), the patient was not allowed to wear a temporary removable prosthesis for the 40 days after the surgery. This waiting period is considerably shorter in the case of autogenous onlay bone grafts fixed with screws, because the allograft biomaterial is constituted of bone granules and has not a rigid architecture. The initial healing time should be long enough to allow the bone graft to become compact, before functional forces are applied.
Ten weeks (75 days) after the surgery, a preimplant computed tomography scan was performed. There was a radiological homogeneity between the grafted bone and the remaining alveolar walls (Fig. 5) . The graft appeared to be integrated.
DISCUSSION
PRF and Metronidazole for Bone Grafting
Choukroun's PRF is a matrix of autologous fibrin, in which are embedded a large quantity of platelet and leukocyte cytokines during centrifugation. 19 -21 The intrinsic incorporation of cytokines within the fibrin mesh implies their progressive release over time, as the network of fibrin disintegrates. At one of its extremities, each PRF clot also concentrates most platelets and leukocytes collected in its 10 mL tube of blood.
The use of this platelet and immune concentrate during bone grafting offers the following 4 advantages:
First, the fibrin clot plays an important mechanical role. Although it does not possess significant adhesive properties (unlike fibrin glues or platelet-rich plasmas), the strength of PRF membranes enables a biomaterial to be maintained and protected against moderate parasitic forces. 33 Moreover, mixed with the graft, PRF fragments serve as a biological connector between bone particles. Soaked in serum, they favor the adhesion of allogeneic bone chips and constitute a biological cement between these fragments. This cohesion gives to the graft a biomechanical strength which is crucial during the first steps of healing, particularly on a site as exposed as the vestibular surface of a maxillary alveolar wall.
Second, the integration of this fibrin network with fragments of allogeneic bone facilitates cellular migration, particularly for endothelial cells necessary for the neo-angiogenesis, 34 vascularization and survival of the graft, as well as for mesenchymal stem cells (drifting or close to wound site). The incorporation of a fibrin network into a grafted mass of lyophilized inactive bone would thus be very positive: paths of cellular migration would appear within the bundles of PRF that vein the graft. Moreover, this fibrin bandage acts as a healing matrix 35 for the soft tissue around the incision and the whole wounded site. Indeed, we can systematically observe a high gingival maturation after healing on PRF membranes, with a thickening of keratinized gingival tissues which improves the esthetic integration and final result of prosthetic rehabilitations. 33 Third, the platelet cytokines, essentially platelet-derived growth factors, transforming growth factor ␤-1, and insulin-like growth factors, seem Fig. 2 . First, the entire surgical site was opened (A). The medullar bone along the vestibular side of the anterior alveolar ridges was stimulated (B). In the posterior area, the 2 sinuses were opened to be filled (C and D). Fig. 3 . The mixture of human lyophilized bone (Phoenix freeze-dried bone allograft, TBF, France) and PRF, soaked in metronidazole, was used to fill the sinuses and to considerably thicken the vestibular side of the anterior and central alveolar ridges (A). PRF membranes were placed to cover the entire grafted area (B). After suturing, the PRF membranes were protected under the flap (C). One day after the graft surgery, healing of the incision line seemed already satisfactory for the protection of the graft underneath.
gradually released as the fibrin matrix is resorbed, thus creating a perpetual process of healing. 20, 28 These mechanisms of gradual release are used by the organism to guide healing and connective tissue remodelling (such as bone), but such a phenomenon is difficult to reproduce synthetically. PRF, however, through physiological polymerization, seems to have this slow release property. It reproduces the elementary mechanisms of hemostasis and healing, on the scale of a fibrin clot which is large enough to be used clinically. In the middle of a bone graft, particularly with lyophilized bone, such a mid-and long-term capacity to maintain healing and remodeling would be extremely beneficial for the maturation of the graft and its overall integration over time. 23 Lastly, the role of PRF in immunity seems significant, because of the presence in the fibrin clot of an important number of leukocytes activated by the centrifugation, and because of the incorporation of inflammatory and anti-inflammatory cytokines into the network of fibrin. 21 The gradual release of these molecules would play a significant role in the self-regulation of inflammatory and infectious phenomena within the grafted material. Indeed, all clinical experiences emphasized that the use of PRF seems to reduce postoperative pain and edemas, and to limit even minor infectious phenomena. The control of inflammation and especially the risk of sepsis within a bone graft seems yet another decisive reason to use PRF during bone grafting.
Metronidazole could be another decisive surgical adjuvant. This antibiotic from the nitro-5-imidazole family is often used orally or applied locally. Incorporated into the graft material during bone graft surgery, it protects against the systematic peroperative contamination by anaerobic bacteria. 36 However, metronidazole will never replace rigorous aseptic conditions during the operation, combined with a general antiseptic covering. This protocol is not an antibiotherapy: 2 mL of this 0.5% solution are containing only 10 mg of metronidazole, i.e., 1/20 of a standard 200 mg oral tablet. This is just enough to limit the contamination of the biomaterial and to protect the early phases of bone construction from infection and the related inflammatory reaction. The local use of this small quantity of metronidazole thus enables the practitioner to increase the quality of maturation of the graft, and to reduce the risk of developing bone infection and, eventually, necrosis.
The combination, within the graft, of these 2 adjuvants seems to increase the radiological and histological quality of the grafted bone tissue. 23 The use of PRF membranes likewise considerably improves the healing and maturation of soft tissue. 33 In this sense, PRF is a healing concentrate: it contains, in a single usable membrane, most key elements of hemostasis and healing.
CONCLUSION
The use of bone substitutes during extensive bone grafting remains a delicate procedure, because of the challenge of adequate integration of the graft. The use of PRF during these interventions offers better postoperative control of the surgical site and seems to accelerate the integration and remodeling of the grafted biomaterial. Combined with existing maxillofacial implant reconstructive therapy, PRF represents a new opportunity to improve grafting procedures, keeping in mind that it is a healing biomaterial and not a "miracle" product. It just increases the potential for therapeutic success when used by a skilled practitioner.
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Fig. 5.
Ten weeks (75 days) after surgery, a preimplant computed tomography scan showed that the graft seemed integrated. There was a complete radiological homogeneity between the grafted bone and the remaining alveolar walls. ABSTRACTO: Los extensos injertos de hueso siguen siendo un procedimiento delicado, debido a la integración lenta y dificultosa del material injertado en la arquitectura fisiológica. El uso reciente de concentrados de plaquetas trata de mejorar este proceso de integración al acelerar la curación del hueso y la mucosa. La fibrina rica en plaquetas de Choukroun (PRF por sus siglas en inglés) es un biomaterial de curación que concentra en una sola membrana de fibrina autóloga la mayoría de las plaquetas, leucocitos y citocinas de una recolección de sangre de 10 mL sin modificación bioquímica artificial (sin anticoagulante, sin trombina de bovinos). Ya sea que se use como membrana o como fragmentos, la PRF permite una protección postoperatoria significativa del lugar quirúrgico y parece acelerar la integración y remodelación del biomaterial injertado. Estas propiedades son particularmente útiles para el injerto de hueso vestibular en las crestas alveolares. Además, proporciona una maduración gingival de muy alta calidad. También se puede usar una pequeña cantidad de solución de metronidazol al 0,5% (10 mg) para proporcionar una protección eficaz del injerto de hueso contra la contaminación inevitable con bacterias anaeróbicas. Este artículo describe una nueva técnica para el injerto de hueso maxilar total previo al implante usando un aloinjerto, las membranas de PRF de Choukroun y metronidazol. Esta primera parte se concentra en el tratamiento reconstructivo previo al implante usando gránulos de hueso alogénico. Las membranas de PRF son particularmente útiles para proteger el lugar quirúrgico y apoyar la curación del tejido suave. Este biomaterial con fibrina representa una nueva oportunidad para mejorar la maduración de los injertos de hueso y el resultado estético final del tejido suave periimplante.
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